(MDXG) MiMedx - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 542m USD | Total Return: -46.1% in 12m
Avg Turnover: 5.70M
Qual. Beats: -1
Rev. Trend: 95.9%
Qual. Beats: -1
Warnings
No concerns identified
Tailwinds
No distinct edge detected
MiMedx Group, Inc. (MDXG) is a biotechnology company specializing in the development and distribution of placental tissue allografts. Utilizing its proprietary PURION process, the company manufactures products from human placental membranes, umbilical cords, and placental discs. These allografts are designed to retain essential biological properties, such as growth factors and cytokines, for use in wound care, burn treatment, and surgical applications including orthopedic and vascular repair.
The company operates within the regenerative medicine sector, a field characterized by high research and development costs and rigorous regulatory oversight for human cells and tissue-based products. MiMedx utilizes a hybrid distribution model, employing a direct sales force alongside independent agents and distributors to reach healthcare providers in the United States. Its product portfolio, including brands like EPIFIX and AMNIOFIX, focuses on minimizing clinical waste through size-specific graft options.
Analyzing the long-term financial health of biotechnology firms on ValueRay can provide deeper insights into their capital allocation strategies. MiMedx maintains its competitive position through patented aseptic processing and terminal sterilization techniques, supported by strategic alliances such as its partnership with Vaporox, Inc. for wound care promotion.
- Medicare reimbursement policy changes for skin substitutes impact wound care revenue
- Expansion of placental tissue allografts into surgical and orthopedic applications
- Direct sales force productivity and independent distributor network growth in US
- Regulatory compliance with FDA human cells and tissue products classifications
- Patent protection and proprietary PURION process integrity against generic competition
| Net Income: 30.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.21 > 0.02 and ΔFCF/TA -0.69 > 1.0 |
| NWC/Revenue: 50.27% < 20% (prev 44.69%; Δ 5.58% < -1%) |
| CFO/TA 0.23 > 3% & CFO 70.6m > Net Income 30.7m |
| Net Debt (-142.2m) to EBITDA (55.4m): -2.57 < 3 |
| Current Ratio: 5.39 > 1.5 & < 3 |
| Outstanding Shares: last quarter (148.4m) vs 12m ago -0.82% < -2% |
| Gross Margin: 81.04% > 18% (prev 0.82%; Δ 8.02k% > 0.5%) |
| Asset Turnover: 134.5% > 50% (prev 130.3%; Δ 4.18% > 0%) |
| Interest Coverage Ratio: 20.39 > 6 (EBITDA TTM 55.4m / Interest Expense TTM 2.07m) |
| A: 0.63 (Total Current Assets 240.3m - Total Current Liabilities 44.5m) / Total Assets 308.7m |
| B: -0.17 (Retained Earnings -53.5m / Total Assets 308.7m) |
| C: 0.15 (EBIT TTM 42.2m / Avg Total Assets 289.5m) |
| D: -0.81 (Book Value of Equity -53.4m / Total Liabilities 65.7m) |
| Altman-Z'' = 3.72 = AA |
| DSRI: 0.67 (Receivables 46.0m/62.3m, Revenue 389.4m/352.4m) |
| GMI: 1.01 (GM 81.04% / 81.88%) |
| AQI: 0.94 (AQ_t 0.21 / AQ_t-1 0.22) |
| SGI: 1.11 (Revenue 389.4m / 352.4m) |
| TATA: -0.13 (NI 30.7m - CFO 70.6m) / TA 308.7m) |
| Beneish M = -3.38 (Cap -4..+1) = AA |
As of May 24, 2026, the stock is trading at USD 3.61 with a total of 1,474,653 shares traded.
Over the past week, the price has changed by +1.69%,
over one month by +9.37%,
over three months by -32.08% and
over the past year by -46.13%.
MiMedx has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy MDXG.
- StrongBuy: 5
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 6.5 | 80.1% |
P/E Forward = 18.315
P/S = 1.3922
P/B = 2.1888
P/EG = 2.875
Revenue TTM = 389.4m USD
EBIT TTM = 42.2m USD
EBITDA TTM = 55.4m USD
Long Term Debt = 16.1m USD (from longTermDebt, last quarter)
Short Term Debt = 1.50m USD (from shortTermDebt, last quarter)
Debt = 17.6m USD (corrected: LT Debt 16.1m + ST Debt 1.50m)
Net Debt = -142.2m USD (calculated: Debt 17.6m - CCE 159.8m)
Enterprise Value = 400.0m USD (542.2m + Debt 17.6m - CCE 159.8m)
Interest Coverage Ratio = 20.39 (Ebit TTM 42.2m / Interest Expense TTM 2.07m)
EV/FCF = 6.11x (Enterprise Value 400.0m / FCF TTM 65.5m)
FCF Yield = 16.38% (FCF TTM 65.5m / Enterprise Value 400.0m)
FCF Margin = 16.82% (FCF TTM 65.5m / Revenue TTM 389.4m)
Net Margin = 7.88% (Net Income TTM 30.7m / Revenue TTM 389.4m)
Gross Margin = 81.04% ((Revenue TTM 389.4m - Cost of Revenue TTM 73.8m) / Revenue TTM)
Gross Margin QoQ = 70.56% (prev 83.86%)
Tobins Q-Ratio = 1.30 (Enterprise Value 400.0m / Total Assets 308.7m)
Interest Expense / Debt = 11.75% (Interest Expense 2.07m / Debt 17.6m)
Taxrate = 26.69% (17.7m / 66.3m)
NOPAT = 30.9m (EBIT 42.2m * (1 - 26.69%))
Current Ratio = 5.39 (Total Current Assets 240.3m / Total Current Liabilities 44.5m)
Debt / Equity = 0.07 (Debt 17.6m / totalStockholderEquity, last quarter 242.9m)
Debt / EBITDA = -2.57 (Net Debt -142.2m / EBITDA 55.4m)
Debt / FCF = -2.17 (Net Debt -142.2m / FCF TTM 65.5m)
Total Stockholder Equity = 238.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 10.60% (Net Income 30.7m / Total Assets 308.7m)
RoE = 10.50% (Net Income TTM 30.7m / Total Stockholder Equity 292.3m)
RoCE = 13.67% (EBIT 42.2m / Capital Employed (Equity 292.3m + L.T.Debt 16.1m))
RoIC = 17.63% (NOPAT 30.9m / Invested Capital 175.3m)
WACC = 9.33% (E(542.2m)/V(559.8m) * Re(9.35%) + D(17.6m)/V(559.8m) * Rd(11.75%) * (1-Tc(0.27)))
Discount Rate = 9.35% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 28.89 | Cagr: 0.11%
[DCF] Terminal Value 73.50% ; FCFF base≈63.0m ; Y1≈68.8m ; Y5≈86.2m
[DCF] Fair Price = 8.52 (EV 1.13b - Net Debt -142.2m = Equity 1.27b / Shares 148.9m; r=9.33% [WACC]; 5y FCF grow 10.57% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -3.43 | # QB: -1
Revenue Correlation: 95.94 | Revenue CAGR: 11.43% | SUE: -0.98 | # QB: -1
EPS current Quarter (2026-06-30): EPS=-0.03 | Chg30d=N/A | Revisions=-33% | Analysts=4
EPS next Quarter (2026-09-30): EPS=-0.00 | Chg30d=-105.00% | Revisions=-33% | Analysts=4
EPS current Year (2026-12-31): EPS=-0.07 | Chg30d=-157.69% | Revisions=-33% | GrowthEPS=-116.7% | GrowthRev=-35.8%
EPS next Year (2027-12-31): EPS=0.12 | Chg30d=-52.43% | Revisions=-33% | GrowthEPS=+263.3% | GrowthRev=+12.4%
[Analyst] Revisions Ratio: -33%